Division of Cardiology, Cardio-Oncology Program, The Ohio State University Medical Center, Columbus, OH, USA; Harrington Heart and Vascular Institute at UH Cleveland Medical Center, Cleveland, OH, USA.
Division of Cardiology, Cardio-Oncology Program, The Ohio State University Medical Center, Columbus, OH, USA.
Resuscitation. 2019 Sep;142:30-37. doi: 10.1016/j.resuscitation.2019.07.005. Epub 2019 Jul 13.
The objective of this study was to determine whether survival and post-arrest procedural utilization following in-hospital cardiac arrest (IHCA) differ in patients with and without comorbid cancer.
We retrospectively reviewed all adult (age ≥18 years old) hospital admissions complicated by IHCA from 2003 to 2014 using the National Inpatient Sample (NIS) dataset. Utilizing propensity score matching using age, gender, race, insurance, all hospital level variables, HCUP mortality score, diabetes, hypertension and cardiopulmonary resuscitation use, rates of survival to hospital discharge and post-arrest procedural utilization were compared.
From 2003 to 2014, there were a total of 1,893,768 hospitalizations complicated by IHCA, of which 112,926 occurred in patients with history of cancer. In a propensity matched cohort from 2012 to 2014, those with cancer were less likely to survive the hospitalization (31% vs. 46%, p < 0.0001). Following an IHCA, rates of procedural utilization in patients with cancer were significantly less when compared to those without a concurrent malignancy: coronary angiography (4.0% vs. 13.0%), percutaneous coronary intervention (2.2% and 8.0%), targeted temperature management (0.8% vs. 6.0%); p < 0.0001 for all comparisons. This patient population was less likely to have acute coronary syndrome (12.6% vs. 27.0%) or congestive heart failure (24.5% vs. 38.2%); p < 0.0001 for both comparisons. Survival improved in both groups over the study period (p < 0.0001).
Patients with a history of cancer who sustain IHCA are less likely to receive post-arrest procedures and survive to hospital discharge. Given the expected rise in the rates of cancer survivorship, these findings highlight the need for broader application of potentially life-saving interventions to lower risk cancer patients who have sustained a cardiac arrest.
本研究旨在确定患有合并症癌症与不患有合并症癌症的院内心脏骤停(IHCA)患者的生存和复苏后程序利用是否存在差异。
我们使用国家住院患者样本(NIS)数据集,回顾性分析了 2003 年至 2014 年期间所有成年(年龄≥18 岁)因 IHCA 住院的患者。利用年龄、性别、种族、保险、所有医院级别变量、HCUP 死亡率评分、糖尿病、高血压和心肺复苏使用情况的倾向评分匹配,比较了生存至出院和复苏后程序利用的比率。
2003 年至 2014 年,共有 1893768 例因 IHCA 住院的患者,其中 112926 例患者有癌症病史。在 2012 年至 2014 年的倾向匹配队列中,患有癌症的患者存活的可能性较小(31%比 46%,p<0.0001)。在发生 IHCA 后,与没有合并恶性肿瘤的患者相比,患有癌症的患者进行程序利用的比率明显较低:冠状动脉造影(4.0%比 13.0%)、经皮冠状动脉介入治疗(2.2%和 8.0%)、目标温度管理(0.8%比 6.0%);所有比较的 p 值均<0.0001。与没有合并恶性肿瘤的患者相比,该患者人群更不可能患有急性冠状动脉综合征(12.6%比 27.0%)或充血性心力衰竭(24.5%比 38.2%);两个比较的 p 值均<0.0001。两组患者在研究期间的生存均有所改善(p<0.0001)。
患有癌症且发生 IHCA 的患者不太可能接受复苏后程序治疗,也无法存活至出院。鉴于癌症幸存者的比例预计会上升,这些发现强调需要更广泛地应用可能救命的干预措施,以降低发生心脏骤停的低危癌症患者的风险。